<?xml version="1.0" encoding="UTF-8" standalone="yes"?><drugRecordOutput id="99481"><DrugName>vutrisiran</DrugName><DrugNamesKey><Name id="43105984">vutrisiran</Name></DrugNamesKey><DrugSynonyms><Name><Value>ALN-TTRsc-02</Value><Types><Type>Research Code</Type></Types></Name><Name><Value>vutrisiran</Value><Types><Type>PINN</Type></Types></Name></DrugSynonyms><CompanyOriginator id="29927">Alnylam Pharmaceuticals Inc</CompanyOriginator><CompaniesPrimary><Company id="29927">Alnylam Pharmaceuticals Inc</Company></CompaniesPrimary><CrossReferences><SourceEntity id="29927" type="Company"><TargetEntity id="4295916167" type="organizationId">Alnylam Pharmaceuticals Inc</TargetEntity></SourceEntity><SourceEntity id="3399" type="ciIndication"><TargetEntity id="D028227" type="MeSH"/><TargetEntity id="85447" type="ORPHANET"/><TargetEntity id="-1689796418" type="omicsDisease"/><TargetEntity id="2878" type="siCondition"/></SourceEntity><SourceEntity id="22390" type="Action"><TargetEntity id="5536" type="Mechanism">TTR Expression Inhibitors</TargetEntity></SourceEntity></CrossReferences><PhaseHighest id="C3">Phase 3 Clinical</PhaseHighest><RegulatoryDesignations><RegulatoryDesignation id="1">Orphan Drug</RegulatoryDesignation></RegulatoryDesignations><IndicationsPrimary><Indication id="3399">Familial amyloid neuropathy</Indication></IndicationsPrimary><ActionsPrimary><Action id="22390">TTR gene inhibitor</Action></ActionsPrimary><ActionsSecondary><Action id="26035">siRNA agent</Action></ActionsSecondary><Technologies><Technology id="647">Subcutaneous formulation</Technology><Technology id="761">Biological therapeutic</Technology><Technology id="103">Oligonucleotide</Technology><Technology id="262">Oligonucleotide conjugated</Technology></Technologies><LastModificationDate>2019-06-28T10:00:23.000Z</LastModificationDate><ChangeDateLast>2019-06-28T00:00:00.000Z</ChangeDateLast><AddedDate>2015-10-22T00:00:00.000Z</AddedDate><DevelopmentProfile><Summary><displayLabel>Summary</displayLabel><value>&lt;Summary&gt;&lt;para&gt;&lt;ulink linkID="29927" linkType="Company"&gt;Alnylam Pharmaceuticals&lt;/ulink&gt; is developing  vutrisiran (formerly ALN-TTRsc-02),  an siRNA therapeutic  targeting   transthyretin (TTR), delivered using a GalNAc-conjugate delivery platform, for the potential once-quarterly, low-volume, sc treatment of transthyretin-mediated amyloidosis (ATTR amyloidosis, familial amyloid polyneuropathy)   [&lt;ulink linkID="1703122" linkType="Reference"&gt;1703122&lt;/ulink&gt;], [&lt;ulink linkID="2005759" linkType="Reference"&gt;2005759&lt;/ulink&gt;], [&lt;ulink linkID="2120024" linkType="Reference"&gt;2120024&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;In January 2019, a phase III trial (HELIOS-A) for hATTR amyloidosis with polyneuropathy was initiated [&lt;ulink linkID="2101569" linkType="Reference"&gt;2101569&lt;/ulink&gt;]. In February 2019, additional phase III studies,  including   in hereditary and wild-type ATTR amyloidosis cardiomyopathy were planned in late 2019 [&lt;ulink linkID="2118030" linkType="Reference"&gt;2118030&lt;/ulink&gt;].&lt;/para&gt;&lt;/Summary&gt;</value></Summary><Regulatory><displayLabel>Regulatory</displayLabel><value>&lt;Regulatory&gt;&lt;para&gt;&lt;subtitle&gt;The US&lt;/subtitle&gt;In May 2018, the FDA granted the product Orphan designation for treatment of transthyretin-mediated amyloidosis (ATTR amyloidosis) [&lt;ulink linkID="2040869" linkType="Reference"&gt;2040869&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Europe&lt;/subtitle&gt;In April 2018, the Committee for Orphan Medicinal Products of the EMA issued a positive opinion recommending vutrisiran for Orphan Drug designation for the treatment of transthyretin-mediated amyloidosis [&lt;ulink linkID="2026663" linkType="Reference"&gt;2026663&lt;/ulink&gt;], [&lt;ulink linkID="2028500" linkType="Reference"&gt;2028500&lt;/ulink&gt;]; in May 2018, the Orphan designation was granted [&lt;ulink linkID="2045345" linkType="Reference"&gt;2045345&lt;/ulink&gt;].&lt;/para&gt;&lt;/Regulatory&gt;</value></Regulatory><Premarketing><displayLabel>Premarketing</displayLabel><value>&lt;Premarketing&gt;&lt;para&gt;&lt;subtitle&gt;Phase III&lt;/subtitle&gt;In February 2019, the company planned to initiate an additional phase III trial (HELIOS-B), of vutrisiran in hereditary and wild-type ATTR amyloidosis patients with cardiomyopathy in late 2019 [&lt;ulink linkID="2118030" linkType="Reference"&gt;2118030&lt;/ulink&gt;], [&lt;ulink linkID="2120024" linkType="Reference"&gt;2120024&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In November 2018, based on the FDA and EMA feedback, a pivotal phase III (HELIOS-A) study  design was planned.  At that time, the trial was expected to initiate in   patients with hATTR amyloidosis polyneuropathy 'later in 2018' [&lt;ulink linkID="2091831" linkType="Reference"&gt;2091831&lt;/ulink&gt;]. In November 2018, a randomized, parallel assigned, open-label, global, phase III trial (&lt;ulink linkID="359546" linkType="Protocol"&gt;NCT03759379&lt;/ulink&gt;; ALN-TTRSC02-002; EudraCT 2018-002098-23; HELIOS-A) to evaluate the efficacy and safety of drug in patients (expected n = 160) with hATTR amyloidosis was planned to be initiated in December 2018. A total of 120 patients were to receive a 25 mg sc injection of vutrisiran once every three months and 40 patients would receive a 0.3 mg/kg iv infusion of &lt;ulink linkID="67037" linkType="Drug"&gt;patisiran&lt;/ulink&gt; once every 3 weeks as a reference comparator. The primary endpoint was change from baseline in the modified neurologic impairment score +7 (mNIS+7) at month 9  and change from baseline in norfolk quality of life-diabetic neuropathy (Norfolk QoL-DN) total score at month 9. At that time, the trial was expected to complete in May 2024 [&lt;ulink linkID="2101569" linkType="Reference"&gt;2101569&lt;/ulink&gt;], [&lt;ulink linkID="2120024" linkType="Reference"&gt;2120024&lt;/ulink&gt;]. In January 2019, the trial was initiated in the US, Bulgaria, France, Malaysia and Portugal,  [&lt;ulink linkID="2101569" linkType="Reference"&gt;2101569&lt;/ulink&gt;], [&lt;ulink linkID="2118030" linkType="Reference"&gt;2118030&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In August 2018,    the company was planning additional phase III  studies, including   in hereditary and wild-type ATTR amyloidosis cardiomyopathy, in 2019 [&lt;ulink linkID="2059688" linkType="Reference"&gt;2059688&lt;/ulink&gt;], [&lt;ulink linkID="2091831" linkType="Reference"&gt;2091831&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In November 2017, a phase III trial was to begin in 2018 [&lt;ulink linkID="1979009" linkType="Reference"&gt;1979009&lt;/ulink&gt;]; in January 2018, it was planned to start in late 2018 [&lt;ulink linkID="1995621" linkType="Reference"&gt;1995621&lt;/ulink&gt;]. In March 2018, a phase III trial was to begin in late 2018 [&lt;ulink linkID="2014054" linkType="Reference"&gt;2014054&lt;/ulink&gt;]. In August 2018, the company reached alignment with the FDA on the design of an open-label, pivotal phase III study with 120 patients. The co-primary endpoints of the trial were mNIS+7 and Norfolk-QOL at nine months by comparing the effect of the drug with placebo arm of phase III APOLLO study patisiran. In addition, certain cardiac parameters were also included as endpoints. An additional reference arm of approximately 30 patients receiving patisiran were to be included. At that time, the company was planning additional phase III  studies, including   wild-type ATTR amyloidosis, in 2019 [&lt;ulink linkID="2059688" linkType="Reference"&gt;2059688&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Phase I&lt;/subtitle&gt;In June 2016, a randomized, placebo-controlled, single ascending-dose, phase I trial (&lt;ulink linkID="263046" linkType="Protocol"&gt;NCT02797847&lt;/ulink&gt;; ALN-TTRSC02-001) was initiated in the UK in healthy volunteers (expected n = 110), to assess the safety of the drug [&lt;ulink linkID="1771140" linkType="Reference"&gt;1771140&lt;/ulink&gt;], [&lt;ulink linkID="1774591" linkType="Reference"&gt;1774591&lt;/ulink&gt;]. In December 2016, preliminary data from the trial were reported. Data demonstrated that a single sc dose of vutrisiran achieved robust TTR knockdown of up to 98.4% with durability for well over four months. At a dose of 50 mg, ALN-TTRsc02 achieved a mean knockdown at day 90 of 86.2% and the drug was well-tolerated [&lt;ulink linkID="1886501" linkType="Reference"&gt;1886501&lt;/ulink&gt;]. In August 2017, data from the trial were presented. Data reported as of May 30, 2017, demonstrated a 95% TTR knockdown with a single 50 mg dose, with durability supportive of a once-quarterly and, possibly, bi-annual subcutaneous dose regimen [&lt;ulink linkID="1979009" linkType="Reference"&gt;1979009&lt;/ulink&gt;], [&lt;ulink linkID="1979981" linkType="Reference"&gt;1979981&lt;/ulink&gt;]. In January 2018, the trial completed  [&lt;ulink linkID="1774591" linkType="Reference"&gt;1774591&lt;/ulink&gt;]. In March 2018, data were presented at the 16th International Symposium on Amyloidosis in Kumamoto, Japan. Treatment with a single dose resulted in a robust TTR knockdown, of mean maximum up to 97% and was maintained over 320 days. Overall the treatment was well tolerated with only mild AEs [&lt;ulink linkID="2017954" linkType="Reference"&gt;2017954&lt;/ulink&gt;].&lt;/para&gt;&lt;/Premarketing&gt;</value></Premarketing><Preclinical><displayLabel>Preclinical</displayLabel><value>&lt;Preclinical&gt;&lt;para&gt;In October 2015, data were presented at the 11th Annual Meeting of the Oligonucleotide Therapeutics Society in Leiden, Netherlands. Initially, a series of ESC-GalNAc-siRNAs targeting TTR were screened for knockdown activity in transgenic mice and NHPs which  led to selection of  vutrisiran.  In NHPs, a single subcutaneous dose at 1 mg/kg led to TTR knockdown of up to 99% with sustained knockdown of more than 50% for greater than 84 days. Monthly subcutaneous dosing at 1 mg/kg achieved sustained TTR knockdown of up to 99% with mean maximal effects greater than 95%.  TTR knockdown activity of vutrisiran was compared to that of &lt;ulink linkID="75438" linkType="Drug"&gt;revusiran&lt;/ulink&gt; which demonstrated that  vutrisiran had a   superior TTR knockdown profile compared with revusiran. In initial rat toxicology studies, vutrisiran was  generally well tolerated  at doses as high as 100 mg/kg. At that time, IND-enabling studies were ongoing [&lt;ulink linkID="1703122" linkType="Reference"&gt;1703122&lt;/ulink&gt;].&lt;/para&gt;&lt;/Preclinical&gt;</value></Preclinical></DevelopmentProfile><IDdbDevelopmentStatus><DevelopmentStatusCurrent><Company id="29927">Alnylam Pharmaceuticals Inc</Company><Country id="MY">Malaysia</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="3399">Familial amyloid neuropathy</Indication><StatusDate>2019-01-18T00:00:00.000Z</StatusDate><Source id="2101569" type="TRIALREG"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="29927">Alnylam Pharmaceuticals Inc</Company><Country id="US">US</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="3399">Familial amyloid neuropathy</Indication><StatusDate>2019-01-18T00:00:00.000Z</StatusDate><Source id="2101569" type="TRIALREG"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="29927">Alnylam Pharmaceuticals Inc</Company><Country id="X5">Europe</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="3399">Familial amyloid neuropathy</Indication><StatusDate>2019-01-18T00:00:00.000Z</StatusDate><Source id="2101569" type="TRIALREG"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="29927">Alnylam Pharmaceuticals Inc</Company><Country id="GB">UK</Country><DevelopmentStatus id="C1" sortOrder="10">Phase 1 Clinical</DevelopmentStatus><Indication id="3399">Familial amyloid neuropathy</Indication><StatusDate>2016-06-09T00:00:00.000Z</StatusDate><Source id="1774591" type="TRIALREG"/></DevelopmentStatusCurrent><DevelopmentStatusHistoric><Company id="29927">Alnylam Pharmaceuticals Inc</Company><Country id="US">US</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="3399">Familial amyloid neuropathy</Indication><StatusDate>2018-05-25T00:00:00.000Z</StatusDate><Source id="2040869" type="CORPORATE"/></DevelopmentStatusHistoric></IDdbDevelopmentStatus><RegulatoryDesignationStatus><Row><RegulatoryDesignation id="1">Orphan Drug</RegulatoryDesignation><OwnerCompany id="29927">Alnylam Pharmaceuticals Inc</OwnerCompany><Country id="EU">EU</Country><Indication id="3399">Familial amyloid neuropathy</Indication><AwardedIndication>Treatment of transthyretin-mediated amyloidosis (ATTR amyloidosis)</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="1">Granted</DesignationApplicationStatus><MileStoneDate>2018-05-25T00:00:00.000Z</MileStoneDate><Source id="2045345" type="PR"/></Row><Row><RegulatoryDesignation id="1">Orphan Drug</RegulatoryDesignation><OwnerCompany id="29927">Alnylam Pharmaceuticals Inc</OwnerCompany><Country id="US">US</Country><Indication id="3399">Familial amyloid neuropathy</Indication><AwardedIndication>Treatment of transthyretin-mediated amyloidosis (ATTR amyloidosis)</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="1">Granted</DesignationApplicationStatus><MileStoneDate>2018-05-25T00:00:00.000Z</MileStoneDate><Source id="2040869" type="CORPORATE"/></Row><Row><RegulatoryDesignation id="1">Orphan Drug</RegulatoryDesignation><OwnerCompany id="29927">Alnylam Pharmaceuticals Inc</OwnerCompany><Country id="EU">EU</Country><Indication id="3399">Familial amyloid neuropathy</Indication><AwardedIndication>Treatment of transthyretin-mediated amyloidosis (ATTR amyloidosis)</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="2">Positive Opinion</DesignationApplicationStatus><MileStoneDate>2018-04-19T00:00:00.000Z</MileStoneDate><Source id="2026663" type="PR"/></Row></RegulatoryDesignationStatus><Targets><Target id="GTGT-02761"><Name>TTR gene</Name><SwissprotNumbers/></Target></Targets><ReasonsForUpdate><ReasonForUpdate><Reason>Editorial Amendments</Reason><Description>Minor editorial amendment</Description></ReasonForUpdate></ReasonsForUpdate><CountsByCompanies><Company><Company id="1009547">Sanofi SA</Company><CountAsPrincipalActive>1</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>1</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company><Company><Company id="29927">Alnylam Pharmaceuticals Inc</Company><CountAsPrincipalActive>0</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>0</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company></CountsByCompanies><CountsByTypes><Type><Type sortOrder="4">Drug - Development/Commercialization License</Type><CountActive>1</CountActive><CountInactive>0</CountInactive><CountTotal>1</CountTotal></Type></CountsByTypes><Deals><Deal id="142304" title="Genzyme to develop Alnylam's RNAi therapeutics worldwide, excluding North America and Western Europe                    "/><Deal id="252041" title="Silence Therapeutics to use patents Alnylam Pharmaceuticals "/></Deals><PatentFamilies><PatentFamily id="4071111" number="WO-2018098117" title="SERPINA1 iRNA compositions and methods of use thereof"/><PatentFamily id="4096059" number="WO-2018112320" title="Methods for treating or preventing TTR-associated diseases using transthyretin (TTR) iRNA compositions"/><PatentFamily id="4398174" number="WO-2019036612" title="Tunable REVERSIR TM compounds"/></PatentFamilies><PatentFamilyCountsByTypes><PatentFamilyCountsByType><Type sortorder="8">General interest</Type><Count>1</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="9">New use</Type><Count>2</Count></PatentFamilyCountsByType></PatentFamilyCountsByTypes><PatentFamilyCountsByCompanies><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Alnylam Pharmaceuticals Inc" id="29927"/><CountAsOwner>3</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>3</CountTotal></PatentFamilyCountsByCompany></PatentFamilyCountsByCompanies><hasSWOTs>N</hasSWOTs></drugRecordOutput>